Verapamil: identification of novel metabolites in cultures of primary human hepatocytes and human urine by LC-MS n and LC-NMR

References

• CHIU, S. H. L. and HUSKEY S. E. W., 1998, Species differences in N-glucuronidation. Drug Metabolism and Disposition, 26, 838–847.
   Google Scholar
• DIETERLE, W., FAIGLE, J. W., KUNG, W. and THEOBALD, W., 1986, The disposition and metabolism of 14C-oxprenolol. HC1. Xenobiotica, 16, 181–191.
   PubMed Web of Science ®Google Scholar
• DUNN, J. C., YARMUSH, M. L., KOEBE, H. G. and TOMPKINS, R. G., 1989, Hepatocyte function and extracellular matrix geometry, long-term culture in a sandwich configuration. FASEB Journal, 3, 174–177.
   PubMed Web of Science ®Google Scholar
• EICHELBAUM, M., ENDE, M., REMBERG, G., SCHOMERUS, M. and DENGLER, H. J., 1979, The metabolism of DL-[14C]verapamil in man. Drug Metabolism and Disposition, 7, 145–148.
   PubMed Web of Science ®Google Scholar
• HAWES, E. M., 1998, N-glucuronidation, a common pathway inhuman metabolism of drugs with a tertiary amine group. Drug Metabolism and Disposition, 26,830–846.
   PubMed Web of Science ®Google Scholar
• HUSKEY, S. W., Doss, G. A., MILLER, R. R., SCHOENS, W. R. and CHiu, H. L., 1994, N-glucuronidation reactions. II. Relative N-glucuronidation reactivity of methylbiphenyl tetrazole, methylbiphenyl triazole, and methylbiphenyl imidazole in rat, monkey, and human hepatic microsomes. Drug Metabolism and Disposition, 22,651–658.
   PubMedGoogle Scholar
• LAETHEM, M. E., LEFEBVRE, R. A., BELPAIRE, F. M., VANHOE, H. L. and BOGAERT, M. G., 1995, Stereoselective pharmacokinetics of oxprenolol and its glucuronides in humans. Clinical Pharmacology and Therapeutics, 57, 419–424.
   PubMedGoogle Scholar
• MCILHENNY, H. M., 1971, Metabolism of [14C] verapamil. Journal of Medical Chemistry, 14, 1178–1184.
   PubMed Web of Science ®Google Scholar
• MEUNIER, C. J. and VERBEECK, R. K., 1999, Glucuronidation of R- and S-ketoprofen, acetaminophen, and difiunisal by liver microsomes of adjuvant-induced arthritic rats. Drug Metabolism and Disposition, 27, 26–31.
   PubMed Web of Science ®Google Scholar
• MILLER, E. C., LOTLIKAR, P. D., MILLER, J. A., BUTLER, B. W., IRVING, C. C. and HILL, J. T., 1968, Reactions in vitro of some tissue nucleophiles with the glucuronide of the carcinogen N-hydroxy-2-acetylaminofluorene, Molecular Pharmacology, 4, 147–154.
   Google Scholar
• MUTLIB, A. E. and NELSON, W. L., 1990, Synthesis and identification of the N-glucuronides of norgallopamil and norverapamil, unusual metabolites of gallopamil and verapamil. Journal of Pharmacology and Experimental Therapeutics, 252, 539–599.
   PubMedGoogle Scholar
• NELSON, W. L. and OLSEN, L. D., 1988, Regiochemistry and enantioselectivity in the oxidative N-dealkylation of verapamil. Drug Metabolism and Disposition, 16, 834–841.
   PubMed Web of Science ®Google Scholar
• NELSON, W. L., OLSEN, L. D., BREITNER, D. B. and BALLOW, R. J., JR, 1987, Regiochemistry and substrate stereoselectivity of O.demethylation of verapamil in the presence of the microsomal fraction from rat and human liver. Drug Metabolism and Disposition, 16, 184–189.
   Google Scholar
• OLSEN, J. A., MOON, R. V., ANDERS, M. W., FENSELAU, C. and SHANE, B., 1992, Enhancement of the biological activity by conjugation reactions. Journal of Nutrition, 122, 615–624.
   PubMedGoogle Scholar
• RITTER, J. K., 2000, Roles of glucuronidation and UDP-glucuronosyltransferases in xenobiotic bioactivation reactions. Chemical and Biological Interactions, 129, 171–193.
   PubMed Web of Science ®Google Scholar
• SCHOMERUS, M., SPIEGELHALDER, B., STIEREN, B. and EICHELBAU M., 1976, Physiological disposition of verapamil in man. Cardiovascular Research, 10, 605–612.
   PubMed Web of Science ®Google Scholar
• SHERRATT, A. J. and DAMANI, L. A., 1989, The metabolism of N,N-dimethylaniline by isolated rat hepatocytes: identification of a novel N-conjugate. Xenobiotica, 19, 379–388.
   PubMed Web of Science ®Google Scholar
• SHOCKCOR, J. P., UNGER, S. E., WILSON, I. D., FOXALL, P. J. D., NICHOLSON, J. K. and LINDON, J. C., 1996, Combined HPLC, NMR spectroscopy, and ion-trap mass spectrometry with application to the detection and characterization of xenobiotic and endogenous metabolites in human urine. Analytical Chemistry, 68, 4431–4435.
   Google Scholar
• SPAHN-LANGGUTH, H. and BENET, L. Z., 1992, Acylglucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism? Drug Metabolism Reviews, 24, 5–47.
   Google Scholar
• SPRAUL, M., HOFMAN, M., WILSON, I. D., LENZ, E., NICHOLSON, J. K. and LINDON, J. C., 1993, Coupling of HPLC with 19F and 1H-spectroscopy to investigate the human excretion of fiurbiprofen metabolites. Journal of Pharmaceutical and Biomedical Analysis, 11, 1009–1015.
   PubMed Web of Science ®Google Scholar
• TETREAULT, S. and ANANTHANARAYANAN, V. S., 1993, Interaction of calcium channel antagonists with calcium: structural studies on verapamil and its Ca2+ complex. Journal of Medicinal Chemistry, 36, 1017–1023.
   PubMedGoogle Scholar
• VOGELSANG, B., ECHIZEN, H., SCHMIDT E. and EICHELBAUM, M., 1984, Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique. British Journal of Clinical Pharmacology, 18, 733–740.
   Google Scholar
• WALLES, M., Thum, T., LEVSEN, K. and BORLAK, J., 2001, Verapamil metabolism in distinct regions of the heart and in cultures of cardiomyocytes of adult rats. Drug Metabolism and Disposition, 29, 761–768.
   PubMed Web of Science ®Google Scholar
• WALLES, M., Thum, T., LEVSEN, K. and BORLAK, J., 2002, Verapamil: new insight into the molecular mechanism of drug oxidation in the human heart. Journal of Chromatography A, 970, 117–130.
   PubMed Web of Science ®Google Scholar
• WALLES, M., Thum, T., LEVSEN, K. and BORLAK, J., 2003, Metabolism of verapamil: 24 new Phase I and Phase II metabolites identified in cell cultures of rat hepatocytes by LC-MS'. Journal of Chromatography B (submitted).
   Google Scholar